Botulinum toxin in urology market is anticipated to grow at a CAGR of 6.4% during the forecast period (2023-2030). The demand for botulinum toxin is rising owing to various factors, including the aging population, a growth in the number of surgeries involving the toxin, and an increased prevalence of neurogenic urologic illnesses such refractory urine incontinence, urgency, and frequency. According to the survey of American Urological Association, in the 35 women with a mean age of 66 years who were enrolled in the study all selective bladder denervation procedures were completed successfully. During 6 months of follow-up the symptom improvement based on 3-day bladder diaries was 59% for urgency urinary incontinence (p <0.001), 59% for urinary incontinence (p <0.001), 39% for urgency (p <0.001), 9% for urinary frequency (p = 0.01) and 27% for the total urgency and frequency score (p <0.001). 

Segmental Outlook 

The global botulinum toxin in urology market is segmented on the application, and end-user. Based on the application, the market is sub-segmented into overactive bladder and neurogenic detrusor overactivity. Further, based on the end-user, the market is sub-segmented into hospitals and urology clinics. Among the end-user, the transparent film dressings sub-segment is anticipated to hold a considerable share of the market, owing to the providing complete list of medications, discussing a treatment plan, and accessibility. 

The Neurogenic Detrusor Overactivity Sub-Segment is Anticipated to Hold a Considerable Share of the Global Botulinum Toxin in Urology Market 

Among the application, the neurogenic detrusor overactivity sub-segment is expected to hold a considerable share of the global botulinum toxin in urology market. Neurogenic detrusor overactivity occurs when there is a communication breakdown between the bladder and spinal cord, as in spina bifida and spinal cord injuries. As a result, the bladder muscle involuntarily contracts, increasing the pressure in the bladder and reducing the bladder capacity, which can cause the individual to leak urine frequently and unexpectedly. Hence, the rising prevalence of chronic diseases has led to an upsurge in neurogenic detrusor overactivity problems, further resultant in market growth. Furthermore, the rising number of food and drug administration (FDA) clearance also attributed to the increasing adoption of botulinum toxin in urology. For instance, in February 2021, Allergan, an AbbVie Inc., received the US FDA approval BOTOX® for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. 

Regional Outlook

The global botulinum toxin in urology market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to hold a prominent share of the market across the globe, owing to the growing aging population coupled with increasing prevalence of urinary incontinence, and well-developed healthcare infrastructure are driving the botulinum toxin in urology market in the Europe. 

Global Botulinum Toxin in Urology Market Growth, by Region, 2023-2030

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Botulinum Toxin in Urology Market 

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. China among other nation is expected to dominate the Asia-Pacific botulinum toxin in urology market followed by India, Japan, South Korea, and the rest of the Asia-Pacific economies. Chinese botulinum toxin in urology market is experiencing a significant growth owing to the growing aging population, high consumption of beverages such as tea and coffee, and diabetes which is leading to increased urinary incontinence. According to the World Health Organization (WHO), China has the highest number of diabetic patients globally, with nearly 116 million active cases in 2019, and is expected to increase to 150 million by 2040. The estimated diabetes prevalence rate in China in 2009 was 3.9% and is projected to increase to 5.4% by 2030. The prevalence of diabetes in Chinese adults aged 20-79 years is projected to increase from 8.2% to 9.7% during 2020-2030. 

Market Players Outlook

The major companies serving the global botulinum toxin in urology market include AbbVie Inc., Merz Pharma, Ipsen Pharma, Galderma Laboratories, L.P., Allergan PLC, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2021, Merz Therapeutics, a business of the Merz Group and a pioneer in the field of neurotoxins, and the Israeli start-up Vensica Therapeuti cs Ltd., a urology company, entered into a strategic license and collaboration agreement for the delivery of botulinum neurotoxin A (Xeomin®)) to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter.

The Report Covers

• Market value data analysis of 2022 and forecast to 2030.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the global botulinum toxin in urology market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.